{"gene":"ITGB3","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":1989,"finding":"Assembly between pro-GPIIb and GPIIIa (ITGB3) is an obligatory prerequisite for maturation of the heterodimer and its expression on the cell surface; unassociated GPIIIa is retained intracellularly and not surface-exposed.","method":"Pulse-chase experiments with antibodies specific for GPIIIa or GPIIb in human megakaryocytes; LAMA-84 megakaryocytic cell line expressing only pro-GPIIb showed no surface expression of GPIIIa until GPIIb processing occurred upon GPIIIa co-expression","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in megakaryocyte culture + cell line complementation experiment, clear functional readout (surface expression), replicated across two experimental systems","pmids":["2477081"],"is_preprint":false},{"year":1991,"finding":"GPIIIa (ITGB3) is phosphorylated in platelets predominantly on threonine; Ca2+/calmodulin-dependent kinase II can phosphorylate purified GPIIIa to ~0.5 mol P/mol in vitro; stoichiometry in intact platelets is very low (~0.01–0.03 mol P/mol), suggesting phosphorylation does not affect bulk fibrinogen-receptor function but may affect a subpopulation.","method":"Metabolic 32Pi labeling of intact platelets; in vitro phosphorylation of purified GPIIb-IIIa by PKC and CaM kinase II; phosphoamino acid analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assay with purified proteins + stoichiometric quantification in intact platelets, single lab with multiple orthogonal methods","pmids":["1650365"],"is_preprint":false},{"year":1992,"finding":"Limited proteolysis of isolated GPIIb/IIIa heterodimer mapped a ligand-binding region to GPIIIa residues 100–220 and identified GPIIIa residues 217–421 as involved in the subunit interface; the GPIIIa N-terminal (1–52) and core (423–622) domains are compact, while the intervening region is proteolysis-susceptible.","method":"Limited proteolysis of purified GPIIb/IIIa with proteinases of different specificities followed by protein-chemical and immunochemical analysis of peptide fragments","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro biochemical dissection with multiple proteinases and immunochemical mapping, single lab, no crystal structure confirmation","pmids":["1546968"],"is_preprint":false},{"year":1994,"finding":"A C→T point mutation at position 2004 in GPIIIa creates an Arg636→Cys substitution that introduces an unpaired cysteine in the cysteine-rich domain, alters N-linked glycosylation (detected as molecular weight shift reversed by EndoH), and creates the Sra alloantigen epitope; despite this, surface expression of GPIIb-IIIa and platelet aggregation are unaffected.","method":"PCR-amplified GPIIIa mRNA sequencing; allele-specific recombinant GPIIIa expression; anti-Sra alloantibody reactivity assay; Endoglycosidase H treatment; SDS-PAGE; platelet aggregation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — recombinant expression with site-specific variant + functional validation (aggregation) + glycosylation mapping, single lab with multiple orthogonal methods","pmids":["8132570"],"is_preprint":false},{"year":1999,"finding":"A homozygous Cys542→Arg substitution in GPIIIa disrupts disulfide bond formation in the cysteine-rich core region, resulting in a slightly slower-migrating GPIIIa by Western blot and trace levels of both GPIIb and GPIIIa at the platelet surface (type I Glanzmann's thrombasthenia), and also reduces αvβ3 surface expression.","method":"Western blotting; flow cytometry with mAbs to GPIIb, GPIIIa, GPIIb-IIIa and αv; PCR-SSCP and direct sequencing; allele-specific restriction enzyme analysis (HinP1I site introduced by mutation)","journal":"British journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (WB, flow cytometry, sequencing, restriction analysis) in single patient/family, clear structure-function link","pmids":["10233432"],"is_preprint":false},{"year":2004,"finding":"F11R (JAM-1) forms a complex with integrin GPIIIa (ITGB3) on platelet surfaces following F11R crosslinking, coincident with F11R dimerization and phosphorylation; this association is part of the signaling cascade leading to platelet aggregation and secretion.","method":"Co-immunoprecipitation of F11R with GPIIIa from activated platelets; functional assays (aggregation, granule secretion); calcium measurements; actin assembly assays","journal":"Journal of receptor and signal transduction research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single co-IP with functional follow-up in platelet system, multiple orthogonal functional assays, single lab","pmids":["15344881"],"is_preprint":false},{"year":2010,"finding":"Several missense mutations in ITGB3 (e.g., C38Y, M118R, G221D) prevent αIIbβ3 complex expression at the COS-7 cell surface; a K253M substitution of β3 defines a key role of K253 in the interaction between the αIIb β-propeller and β3 β-I domains, as revealed by free energy analysis on the resolved αIIbβ3 crystal structure.","method":"Site-directed mutagenesis; transient expression in COS-7 cells; flow cytometry; structural free energy analysis on solved αIIbβ3 structure; molecular modeling","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis + cell surface expression assay + structural modeling on solved crystal structure, multiple mutations tested, single lab","pmids":["20020534"],"is_preprint":false},{"year":2011,"finding":"ROS upregulate ITGB3 expression in colorectal cancer cells, and surface expression as αvβ3 heterodimer is required for ITGB3-mediated migration and invasion; ITGB3 promotes aggressive phenotype through the PI3K-Akt-mTOR pathway and upregulation of STMN1.","method":"2D-electrophoresis proteomics; knockdown of ITGB3 by siRNA in SW620 and H2O2-treated SW480 cells; Transwell migration/invasion assays; Western blot; ROS measurement","journal":"Molecular & cellular proteomics : MCP","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function KD with defined phenotypic readout + pathway analysis, single lab, multiple orthogonal methods","pmids":["21622897"],"is_preprint":false},{"year":2011,"finding":"Integrin β3 (CD61) signaling is required for sustaining active TGFβ signaling and self-renewal of breast tumor-initiating cells in the MMTV-Her2/neu model; pharmacological inhibition of TGFβ signaling suppressed TIC self-renewal and clonogenicity.","method":"CD49f/CD61 surface marker sorting; tumorsphere formation assay; in vivo tumorigenicity; TGFβ pathway inhibition; gene expression profiling","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function pharmacological inhibition with functional phenotype (self-renewal, tumorigenicity), single lab, multiple assays","pmids":["21996747"],"is_preprint":false},{"year":2017,"finding":"ITGB3 is translationally activated under hypoxia in breast cancer cells (mTOR-independent mechanism), and is required for sustained TGF-β pathway activation and induction of Snail/EMT markers; ITGB3 knockdown increased apoptosis, reduced migration, and significantly reduced lung metastasis in mice.","method":"Polysomal RNA-Seq (translatome profiling); ITGB3 knockdown; apoptosis assays; TGF-β pathway reporter; EMT marker analysis; in vivo lung metastasis mouse model","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 / Strong — translatome profiling + KD with multiple orthogonal functional readouts (apoptosis, migration, EMT, in vivo metastasis) and pathway mechanistic link","pmids":["29383126"],"is_preprint":false},{"year":2018,"finding":"G9A promotes ITGB3 expression in gastric cancer by forming a transcriptional activator complex with P300 and glucocorticoid receptor (GR) at the ITGB3 promoter, an effect dependent on dexamethasone but independent of G9A's SET domain methyltransferase activity.","method":"Chromatin immunoprecipitation (ChIP); co-immunoprecipitation of G9A/P300/GR complex; luciferase reporter assay; ITGB3 overexpression/knockdown; in vitro and in vivo invasion/metastasis assays; SET domain mutant constructs","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP, reciprocal co-IP, reporter assay, and mutant constructs establishing transcriptional mechanism, single lab with multiple orthogonal methods","pmids":["29449539"],"is_preprint":false},{"year":2018,"finding":"ITGB3 depletion sensitizes mesenchymal lung cancer cells to conventional chemotherapeutic drugs by modulating the NF-κB signaling pathway.","method":"ITGB3 knockdown; cell viability assays; NF-κB signaling pathway analysis; large-scale transcriptome and drug-response dataset correlation","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — KD with defined pathway readout (NF-κB) and chemosensitivity phenotype, single lab, limited mechanistic depth in abstract","pmids":["30563517"],"is_preprint":false},{"year":2019,"finding":"ITGB3 promoter variant rs55827077 (C allele) enhances ITGB3 promoter activity specifically during megakaryocyte differentiation, leading to greater integrin β3 protein expression, enhanced SERT trafficking from cytosol to platelet plasma membrane, and elevated serotonin blood levels.","method":"Luciferase reporter assays in K-562 and HEL 92.1.7 hematopoietic cell lines; ITGB3 sequencing; platelet integrin β3 protein quantification; SERT trafficking assay; association analysis in 176 autistic individuals","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional promoter reporter assay + protein expression measurement + SERT trafficking assay, replicated across cell lines and associated with human phenotype data","pmids":["30535103"],"is_preprint":false},{"year":2020,"finding":"ITGB3 facilitates uptake of small extracellular vesicles in breast cancer cells through interaction with heparan sulfate proteoglycans (HSPGs) and integrin endocytosis; this requires activation of focal adhesion kinase (FAK), which is necessary for endocytosis-mediated internalization of vesicles.","method":"ITGB3 knockdown/overexpression; vesicle uptake assays; Co-IP of ITGB3 with HSPGs; FAK inhibition; endocytosis inhibitor experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction data + KD/KO with defined cellular phenotype + FAK pathway validation, single lab with multiple orthogonal methods","pmids":["32848136"],"is_preprint":false},{"year":2020,"finding":"In melanoma tumor-repopulating cells, ITGB3 activates c-SRC, which phosphorylates STAT3; STAT3 transcriptionally suppresses RIG-I, thereby decreasing STAT1 activation and conferring resistance to IFN-α-induced apoptosis.","method":"ITGB3/c-SRC/STAT3 knockdown; ChIP-qPCR for STAT3 binding to RIG-I promoter; Co-IP of SHP-1 with STAT1; Western blot; apoptosis assays; in vivo tumor models","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR + co-IP + KD with defined apoptosis phenotype + in vivo validation, single lab with multiple orthogonal methods establishing signaling pathway","pmids":["32152220"],"is_preprint":false},{"year":2020,"finding":"EGFL7 binds to and activates ITGB3 on multiple myeloma cells, causing ITGB3 phosphorylation and focal adhesion kinase activation; ITGB3 overexpression upregulates KLF2 transcription factor, which in turn enhances EGFL7 transcription, establishing an EGFL7-ITGB3-KLF2 amplification loop supporting MM cell survival.","method":"ITGB3 and EGFL7 overexpression/knockdown; ITGB3 phosphorylation assay; FAK activation measurement; KLF2 reporter; neutralizing antibody treatment; in vivo mouse transplantation model","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 2 / Moderate — phosphorylation assay + multiple KD/KO + reporter assay + in vivo model, single lab with multiple orthogonal methods","pmids":["32191808"],"is_preprint":false},{"year":2019,"finding":"miR-30 family deficiency activates calcineurin-NFATC signaling, which in turn activates uPAR-ITGB3 signaling in podocytes, leading to Rho GTPase activation, synaptopodin downregulation and podocyte injury; ITGB3 inhibition, calcineurin inhibition, or NFATC inhibition each reduces the effects of miR-30 knockdown.","method":"Podocyte-specific miR-30 KO and transgenic mice; ITGB3 inhibitor treatment; calcineurin/NFATC inhibitors; uPAR/ITGB3 pathway measurement; proteinuria readout; LPS model","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO + pharmacological rescue + multiple inhibitors establishing pathway epistasis, in vivo and in vitro corroboration","pmids":["31127093"],"is_preprint":false},{"year":2021,"finding":"HOXB5 transcriptionally activates ITGB3 expression by directly binding to the ITGB3 promoter (chromatin immunoprecipitation + luciferase assay), promoting colorectal cancer metastasis; CXCL12 upregulates HOXB5 via ERK/ETS1 pathway, creating a CXCL12-HOXB5-CXCR4 positive feedback loop.","method":"Chromatin immunoprecipitation (ChIP); luciferase reporter assay; HOXB5 overexpression/knockdown; in vivo lung and liver metastasis models","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP and luciferase reporter directly establishing transcriptional regulation + in vivo metastasis validation, single lab with multiple orthogonal methods","pmids":["33456563"],"is_preprint":false},{"year":2021,"finding":"Loss of ITGB3 in ovine conceptus trophectoderm decreases embryo growth and reduces expression of SPP1 and NOS3 in the placental allantoic membrane, implicating ITGB3 in regulation of placental vascular development.","method":"Morpholino antisense oligonucleotide knockdown of ITGB3 in sheep uterus; measurement of embryo growth; qPCR and immunolocalization of SPP1 and NOS3","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo morpholino KD with defined molecular phenotype (NOS3, SPP1 reduction) and growth readout, single lab","pmids":["33232974"],"is_preprint":false},{"year":2021,"finding":"IL1RN interacts with ITGB3 (integrin β3) to activate β-catenin signaling, which regulates osteoblast differentiation; IL1RN overexpression promotes osteogenic markers and IL1RN silencing attenuates osteogenesis.","method":"Co-immunoprecipitation of IL1RN and ITGB3; IL1RN overexpression/knockdown in MC3T3-E1 and C3H10T1/2 cells; osteogenic staining and marker expression; β-catenin signaling measurement","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single co-IP with functional follow-up (gain/loss of function + pathway measurement), single lab","pmids":["33493267"],"is_preprint":false},{"year":2022,"finding":"ITGB3 haplo-insufficiency in cortical neurons impairs network excitability by promoting extra-synaptic over synaptic mGluR5 signaling; CRISPR activation of Itgb3 to restore gene dosage rebalanced network excitability as effectively as MPEP (mGluR5 antagonist) blockade.","method":"Itgb3 knockout mice; CRISPR activation (CRISPRa) to restore Itgb3 expression; cortical network excitability recording; mGluR5 pharmacological manipulation; biochemical and imaging analyses","journal":"Molecular therapy. Nucleic acids","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO + CRISPRa rescue + pharmacological epistasis establishing functional interaction with mGluR5, multiple orthogonal methods in single study","pmids":["36035754"],"is_preprint":false},{"year":2022,"finding":"P-EV (platelet-derived extracellular vesicle)-upregulated ITGB3 increases SLC7A11 expression by enhancing protein stability and activating the MAPK/ERK/ATF4/Nrf2 axis, suppressing ferroptosis and facilitating NPC cell metastasis.","method":"EV transfer experiments; ITGB3 overexpression/knockdown; SLC7A11 protein stability assay; MAPK/ERK/ATF4/Nrf2 pathway analysis; ferroptosis assays; NPC xenograft mouse model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function + pathway analysis + in vivo validation, single lab","pmids":["36263165"],"is_preprint":false},{"year":2022,"finding":"MIIP directly interacts with ITGB3 via an RGD motif, suppresses ITGB3 downstream signaling, reduces β-catenin (via ubiquitin-mediated degradation), decreases VEGFA production and EMT, thereby inhibiting tumor angiogenesis and metastasis of triple-negative breast cancer.","method":"Co-immunoprecipitation of MIIP and ITGB3; RGD motif mutagenesis; β-catenin ubiquitination assay; VEGFA expression; in vivo tumor models","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct binding shown by co-IP + RGD motif mutagenesis validating binding site + downstream pathway and in vivo functional readout, single lab with multiple orthogonal methods","pmids":["36130933"],"is_preprint":false},{"year":2023,"finding":"ITCH (ubiquitin E3 ligase) interacts with ITGB3 and mediates its ubiquitylation; ITCH overexpression opposes ITGB3-promoted proliferation and invasion of ectopic endometrial stromal cells, suggesting ubiquitination of ITGB3 regulates its stability/activity.","method":"Co-immunoprecipitation of ITCH and ITGB3; ubiquitylation analysis; CCK8 proliferation assay; Transwell invasion assay; ITGB3 and ITCH overexpression","journal":"Biomedicines","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with ubiquitylation assay + functional rescue experiments, single lab","pmids":["37760946"],"is_preprint":false},{"year":2024,"finding":"ITGB3 (CD61) is transiently expressed on T cells, pairs with CD103 at synaptic microclusters, and colocalizes with the TCR; CD61 modulates downstream TCR signaling and enhances antitumor cytotoxicity.","method":"Live imaging of synaptic microclusters; co-localization of CD61 with CD103 and TCR; TCR signaling pathway analysis; cytotoxicity assays; in vivo tumor growth control experiments","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — imaging of CD61/CD103/TCR colocalization at immune synapse + functional cytotoxicity assays + in vivo tumor control, single study with multiple orthogonal methods","pmids":["38561495"],"is_preprint":false},{"year":2024,"finding":"PEX3-regulated plasmalogen metabolism activates the AKT/GSK3β signaling pathway via plasma membrane localization of ITGB3, promoting myocardial regenerative repair; cardiomyocyte-specific Pex3 KO disrupts ITGB3 plasma membrane localization.","method":"Cardiomyocyte-specific Pex3 KO mice; lipid metabolomics; ITGB3 plasma membrane fractionation; AKT/GSK3β signaling measurement; myocardial regeneration readouts","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO + metabolomics + subcellular fractionation establishing ITGB3 membrane localization mechanism + signaling pathway, single lab","pmids":["38951640"],"is_preprint":false},{"year":2017,"finding":"Laminin (ECM protein) enhances MSC paracrine function (GRO-α, HGF, IL-8 secretion) through αvβ3 integrin (ITGB3), with GRO-α and IL-8 secretion dependent on JNK signaling and HGF secretion dependent on PI3K/AKT signaling downstream of αvβ3.","method":"αvβ3 integrin blocking antibody; JNK and PI3K/AKT inhibitors; paracrine factor ELISA; cardiomyocyte apoptosis assay","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor blocking + pathway inhibitors with defined secretion phenotype, single lab, multiple signaling arms validated","pmids":["28600799"],"is_preprint":false},{"year":2018,"finding":"Osteocytes sense ECM mechanical stiffness via integrin αvβ3 (containing ITGB3), which interacts with FAK to transduce extracellular mechanical stimuli into intracellular signals; FAK triggers cytoplasmic β-catenin signaling and nuclear translocation, affecting gap junction function and mineralization activity.","method":"PDMS substrates with varied mechanical stiffness; ITGB3/FAK inhibitor experiments; β-catenin nuclear localization assay; gap junction and mineralization activity measurement","journal":"ACS applied bio materials","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanically defined substrate + inhibitor experiments establishing ITGB3-FAK-β-catenin pathway in mechanosensing, single lab","pmids":["34996170"],"is_preprint":false}],"current_model":"ITGB3 (integrin β3/GPIIIa/CD61) encodes the β3 subunit of the αIIbβ3 fibrinogen receptor and αvβ3 vitronectin receptor; it requires assembly with pro-αIIb in the ER as a prerequisite for surface expression, is phosphorylated at low stoichiometry by CaM kinase II on threonine residues, mediates outside-in signaling through FAK activation to drive migration, invasion, vesicle endocytosis, and TGF-β/mGluR5 pathway regulation; its expression is transcriptionally regulated by HOXB5 and G9A/P300/GR complexes, translationally activated by hypoxia, post-translationally controlled by ITCH-mediated ubiquitylation, and at the platelet surface it forms signaling complexes with F11R/JAM-A; through a protein complex involving integrin β3, platelet SERT trafficking to the membrane is regulated, linking ITGB3 to serotonin blood levels; and in T cells, transient CD61 expression at the immune synapse with CD103 potentiates TCR signaling and antitumor cytotoxicity."},"narrative":{"mechanistic_narrative":"ITGB3 (integrin β3/GPIIIa/CD61) is the β-subunit of integrin heterodimers that transduce extracellular adhesion cues into intracellular signaling controlling platelet aggregation, cell migration, invasion, and tissue remodeling [PMID:2477081, PMID:21622897]. Surface display of the receptor is conditional: GPIIIa must assemble with pro-GPIIb in the ER as an obligatory prerequisite for heterodimer maturation, and unassembled GPIIIa is retained intracellularly [PMID:2477081]; mutations disrupting subunit-interface contacts or disulfide bonding in the cysteine-rich region abolish surface expression of both αIIbβ3 and αvβ3, causing Glanzmann's thrombasthenia [PMID:10233432, PMID:20020534]. Engagement of αvβ3 drives outside-in signaling principally through focal adhesion kinase (FAK), which couples the receptor to integrin endocytosis and extracellular-vesicle uptake, to β-catenin nuclear translocation during mechanosensing, and to PI3K/AKT- and JNK-dependent outputs [PMID:32848136, PMID:34996170, PMID:28600799]. Across multiple cancers, ITGB3 sustains TGF-β signaling, EMT, and metastasis, and engages additional effector axes including PI3K-Akt-mTOR/STMN1, c-SRC/STAT3, NF-κB, and EGFL7-KLF2 amplification loops [PMID:21622897, PMID:29383126, PMID:32152220, PMID:32191808]. ITGB3 abundance is set at several levels: transcriptionally by HOXB5 and by a G9A/P300/glucocorticoid-receptor activator complex, translationally by hypoxia, and post-translationally by ITCH-mediated ubiquitylation; a promoter variant raising β3 expression in megakaryocytes enhances SERT trafficking to the platelet membrane and elevates blood serotonin [PMID:33456563, PMID:29449539, PMID:29383126, PMID:37760946, PMID:30535103]. Beyond hemostasis and cancer, ITGB3 acts as a uPAR-linked effector of calcineurin-NFATC signaling in podocyte injury, regulates cortical network excitability by balancing synaptic versus extrasynaptic mGluR5 signaling, and is transiently expressed on T cells where it pairs with CD103 at the immune synapse to potentiate TCR signaling and antitumor cytotoxicity [PMID:31127093, PMID:36035754, PMID:38561495].","teleology":[{"year":1989,"claim":"Established that GPIIIa cannot reach the cell surface alone, defining heterodimer assembly with pro-GPIIb as the gatekeeping step for receptor biogenesis.","evidence":"Pulse-chase with subunit-specific antibodies in human megakaryocytes and complementation in the LAMA-84 cell line","pmids":["2477081"],"confidence":"High","gaps":["Did not define the ER chaperones or quality-control machinery enforcing retention","Does not address αvβ3 assembly requirements"]},{"year":1991,"claim":"Determined that GPIIIa is phosphorylated on threonine by CaM kinase II, but at stoichiometry too low to regulate bulk fibrinogen-receptor function.","evidence":"32Pi metabolic labeling of platelets plus in vitro phosphorylation of purified GPIIb-IIIa and phosphoamino acid analysis","pmids":["1650365"],"confidence":"High","gaps":["Physiological role of the low-stoichiometry phosphorylation not resolved","Specific phosphoacceptor residues not mapped"]},{"year":1992,"claim":"Mapped the ligand-binding and subunit-interface regions of GPIIIa by proteolytic dissection, providing the first domain-level structure-function framework.","evidence":"Limited proteolysis of purified GPIIb/IIIa with multiple proteinases and immunochemical fragment mapping","pmids":["1546968"],"confidence":"Medium","gaps":["No crystal structure confirmation at the time","Boundaries inferred from protease accessibility rather than direct contact mapping"]},{"year":2010,"claim":"Connected disease mutations to receptor assembly defects and identified specific β3 residues governing the αIIb β-propeller/β3 β-I domain interface.","evidence":"Site-directed mutagenesis and COS-7 surface expression assays combined with free-energy analysis on the solved αIIbβ3 crystal structure","pmids":["20020534","10233432","8132570"],"confidence":"High","gaps":["Does not address how interface defects are sensed by ER quality control","Some variants (e.g. Sra) alter glycosylation without affecting function, leaving structural consequences unexplained"]},{"year":2004,"claim":"Identified a platelet-surface signaling partnership in which F11R/JAM-A associates with GPIIIa during platelet activation.","evidence":"Co-immunoprecipitation from activated platelets with functional aggregation, secretion, calcium and actin assays","pmids":["15344881"],"confidence":"Medium","gaps":["Single co-IP without reciprocal validation","Direct versus indirect nature of the association not established"]},{"year":2017,"claim":"Defined αvβ3 as the receptor coupling laminin engagement to MSC paracrine secretion through branched JNK and PI3K/AKT outputs.","evidence":"αvβ3 blocking antibody plus JNK and PI3K/AKT inhibitors with paracrine factor ELISA","pmids":["28600799"],"confidence":"Medium","gaps":["Antibody blockade does not exclude contribution of other αv heterodimers","Mechanism connecting receptor to divergent kinase arms not detailed"]},{"year":2011,"claim":"Showed that ITGB3 drives tumor migration/invasion and TGF-β-dependent tumor-initiating-cell self-renewal, placing the receptor upstream of cancer-progression programs.","evidence":"siRNA knockdown with Transwell assays and PI3K-Akt-mTOR/STMN1 analysis; CD49f/CD61 sorting with tumorsphere and in vivo tumorigenicity assays plus TGF-β inhibition","pmids":["21622897","21996747"],"confidence":"Medium","gaps":["How ROS upregulates ITGB3 transcription not defined","Direct molecular link between β3 and TGF-β receptor activation not resolved"]},{"year":2017,"claim":"Established that ITGB3 abundance is set translationally under hypoxia and is required for sustained TGF-β/EMT signaling and metastasis.","evidence":"Polysomal RNA-Seq translatome profiling plus knockdown with apoptosis, migration, EMT readouts and in vivo lung metastasis","pmids":["29383126"],"confidence":"High","gaps":["mTOR-independent translational mechanism not molecularly identified","Effector linking β3 to Snail induction unspecified"]},{"year":2018,"claim":"Identified multiple transcriptional and signaling inputs setting or transmitting ITGB3 levels in cancer, including a non-catalytic G9A/P300/GR activator complex and NF-κB-linked chemoresistance.","evidence":"ChIP, reciprocal co-IP, luciferase reporters and SET-domain mutants for G9A complex; knockdown with NF-κB pathway and drug-response analysis for mesenchymal lung cancer","pmids":["29449539","30563517"],"confidence":"High","gaps":["Generality of glucocorticoid-dependent ITGB3 induction beyond gastric cancer untested","Mechanism linking β3 to NF-κB activation not defined"]},{"year":2019,"claim":"Linked an ITGB3 promoter variant to megakaryocyte-specific β3 expression, SERT membrane trafficking, and blood serotonin, connecting integrin dosage to a neurotransmitter phenotype.","evidence":"Luciferase reporters in hematopoietic cell lines, platelet β3 quantification, SERT trafficking assay, and human association analysis","pmids":["30535103"],"confidence":"High","gaps":["Molecular mechanism by which β3 promotes SERT membrane trafficking unresolved","Causality between serotonin elevation and phenotype not established"]},{"year":2019,"claim":"Placed ITGB3 as a downstream effector in the miR-30/calcineurin-NFATC/uPAR axis driving podocyte injury.","evidence":"Podocyte-specific miR-30 KO/transgenic mice with ITGB3, calcineurin and NFATC inhibitors and proteinuria readouts","pmids":["31127093"],"confidence":"High","gaps":["Direct uPAR-ITGB3 binding versus signaling crosstalk not dissected","Rho GTPase activation mechanism downstream of β3 not detailed"]},{"year":2020,"claim":"Defined FAK-dependent outside-in signaling roles for ITGB3 in vesicle endocytosis and in SRC/STAT3 and EGFL7-KLF2 survival circuits.","evidence":"Knockdown/overexpression with reciprocal co-IP (HSPGs, EGFL7), FAK inhibition, ChIP-qPCR, phosphorylation and in vivo models across breast cancer, melanoma and myeloma","pmids":["32848136","32152220","32191808"],"confidence":"High","gaps":["Whether a single β3 conformation drives all these effector branches unknown","Cell-type determinants selecting among SRC/STAT3, KLF2 and FAK outputs unresolved"]},{"year":2021,"claim":"Identified HOXB5 as a direct transcriptional activator of ITGB3 in a CXCL12-CXCR4 feedback loop and extended ITGB3 function to placental vascular development and osteoblast differentiation.","evidence":"ChIP and luciferase reporters with in vivo metastasis for HOXB5; morpholino knockdown in sheep conceptus; IL1RN-ITGB3 co-IP with β-catenin/osteogenesis assays","pmids":["33456563","33232974","33493267"],"confidence":"Medium","gaps":["IL1RN-ITGB3 interaction rests on a single co-IP","Mechanism by which β3 controls SPP1/NOS3 in placenta not defined"]},{"year":2022,"claim":"Expanded ITGB3 regulation and signaling to RGD-mediated suppression by MIIP, ferroptosis evasion via SLC7A11, and neuronal control of mGluR5-dependent network excitability.","evidence":"Co-IP with RGD-motif mutagenesis and β-catenin ubiquitination (MIIP); EV transfer with SLC7A11 stability and MAPK/ERK/ATF4/Nrf2 analysis; Itgb3 KO mice with CRISPRa rescue and mGluR5 pharmacology","pmids":["36130933","36263165","36035754"],"confidence":"High","gaps":["Whether synaptic mGluR5 regulation involves canonical integrin adhesion signaling unknown","Structural basis of MIIP RGD-mediated inhibition versus ligand activation not contrasted"]},{"year":2023,"claim":"Established ITCH-mediated ubiquitylation as a post-translational control of ITGB3 stability and pro-invasive activity.","evidence":"Co-IP of ITCH with ITGB3, ubiquitylation analysis, and proliferation/invasion rescue in ectopic endometrial stromal cells","pmids":["37760946"],"confidence":"Medium","gaps":["Ubiquitylated lysine residues and chain type not mapped","Whether ITCH targets cell-surface or intracellular β3 pools unclear"]},{"year":2024,"claim":"Revealed non-canonical contexts: transient CD61 expression at the T-cell immune synapse potentiating TCR signaling, and PEX3-dependent plasmalogen metabolism controlling ITGB3 membrane localization in cardiac repair.","evidence":"Live synaptic imaging with CD61/CD103/TCR colocalization and cytotoxicity assays; cardiomyocyte-specific Pex3 KO with lipidomics, membrane fractionation and AKT/GSK3β analysis","pmids":["38561495","38951640"],"confidence":"High","gaps":["How CD61 mechanistically modulates TCR proximal signaling not defined","Lipid-dependent mechanism positioning β3 at the plasma membrane not molecularly resolved"]},{"year":null,"claim":"It remains unresolved how a single β3 subunit selects among its diverse outside-in effector branches (FAK, SRC/STAT3, β-catenin, NF-κB, mGluR5) in a cell-type- and ligand-specific manner.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying conformational or partner-selection model across tissues","Relationship between phosphorylation, ubiquitylation and effector choice unmapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,13,26,27]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[13,27,14,15,16]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[5,27]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,12,25]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,14,15,16,27]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0,5,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,9,14,15,22]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[13]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[10,17]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[23,1]}],"complexes":["αIIbβ3 (GPIIb-IIIa)","αvβ3 integrin"],"partners":["ITGAV","ITGA2B","F11R","EGFL7","MIIP","IL1RN","ITCH","CD103"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P05106","full_name":"Integrin beta-3","aliases":["Platelet membrane glycoprotein IIIa","GPIIIa"],"length_aa":788,"mass_kda":87.1,"function":"Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain (By similarity). Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen (PubMed:9111081). This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity). ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415, PubMed:24789099). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887). In brain, plays a role in synaptic transmission and plasticity. Involved in the regulation of the serotonin neurotransmission, is required to localize to specific compartments within the synapse the serotonin receptor SLC6A4 and for an appropriate reuptake of serotonin. Controls excitatory synaptic strength by regulating GRIA2-containing AMPAR endocytosis, which affects AMPAR abundance and composition (By similarity). ITGAV:ITGB3 act as a receptor for CD40LG (PubMed:31331973). ITGAV:ITGB3 acts as a receptor for IBSP and promotes cell adhesion and migration to IBSP (PubMed:10640428). Integrin ITGA2B:ITGB3 is also the receptor of the erythrocyte-specific ICAM4 ligand involved in heterotypic cell-cell adhesion between erythrocytes and activated platelets (PubMed:12477717) (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Herpes virus 8/HHV-8 (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Coxsackievirus A9 (Microbial infection) Acts as a receptor for Hantaan virus (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Cytomegalovirus/HHV-5 (Microbial infection) Integrin ITGA5:ITGB3 acts as a receptor for Human metapneumovirus (Microbial infection) Integrin ITGAV:ITGB3 acts aP05556s a receptor for Human parechovirus 1 (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for West nile virus (Microbial infection) In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions","subcellular_location":"Cell membrane; Cell projection, lamellipodium membrane; Cell junction, focal adhesion; Postsynaptic cell membrane; Synapse","url":"https://www.uniprot.org/uniprotkb/P05106/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ITGB3","classification":"Not Classified","n_dependent_lines":47,"n_total_lines":1208,"dependency_fraction":0.03890728476821192},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ITGB3","total_profiled":1310},"omim":[{"mim_id":"621266","title":"FETOMATERNAL ALLOIMMUNE THROMBOCYTOPENIA 2; FMAIT2","url":"https://www.omim.org/entry/621266"},{"mim_id":"621264","title":"FETOMATERNAL ALLOIMMUNE THROMBOCYTOPENIA 1; FMAIT1","url":"https://www.omim.org/entry/621264"},{"mim_id":"620845","title":"TRANSMEMBRANE 4 L6 FAMILY, MEMBER 19; TM4SF19","url":"https://www.omim.org/entry/620845"},{"mim_id":"620776","title":"THROMBOCYTOPENIA 13, SYNDROMIC; THC13","url":"https://www.omim.org/entry/620776"},{"mim_id":"619271","title":"BLEEDING DISORDER, PLATELET-TYPE, 24; BDPLT24","url":"https://www.omim.org/entry/619271"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":37.6},{"tissue":"thyroid gland","ntpm":52.7}],"url":"https://www.proteinatlas.org/search/ITGB3"},"hgnc":{"alias_symbol":["CD61","GPIIIa"],"prev_symbol":["GP3A"]},"alphafold":{"accession":"P05106","domains":[{"cath_id":"3.30.1680.10","chopping":"28-84","consensus_level":"medium","plddt":89.4598,"start":28,"end":84},{"cath_id":"2.60.40.1510","chopping":"87-135_383-458","consensus_level":"medium","plddt":90.3691,"start":87,"end":458},{"cath_id":"3.40.50.410","chopping":"139-379","consensus_level":"high","plddt":95.1142,"start":139,"end":379},{"cath_id":"2.10.25.10","chopping":"557-588","consensus_level":"medium","plddt":90.8084,"start":557,"end":588},{"cath_id":"4.10.1240.30","chopping":"634-709","consensus_level":"high","plddt":84.2089,"start":634,"end":709}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05106","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05106-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05106-F1-predicted_aligned_error_v6.png","plddt_mean":87.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ITGB3","jax_strain_url":"https://www.jax.org/strain/search?query=ITGB3"},"sequence":{"accession":"P05106","fasta_url":"https://rest.uniprot.org/uniprotkb/P05106.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05106/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05106"}},"corpus_meta":[{"pmid":"31331909","id":"PMC_31331909","title":"Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31331909","citation_count":290,"is_preprint":false},{"pmid":"21917754","id":"PMC_21917754","title":"Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21917754","citation_count":176,"is_preprint":false},{"pmid":"23981581","id":"PMC_23981581","title":"MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23981581","citation_count":176,"is_preprint":false},{"pmid":"21996747","id":"PMC_21996747","title":"CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21996747","citation_count":139,"is_preprint":false},{"pmid":"32848136","id":"PMC_32848136","title":"ITGB3-mediated uptake of small extracellular vesicles facilitates intercellular communication in breast cancer cells.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32848136","citation_count":132,"is_preprint":false},{"pmid":"21622897","id":"PMC_21622897","title":"Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells.","date":"2011","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/21622897","citation_count":111,"is_preprint":false},{"pmid":"17203304","id":"PMC_17203304","title":"Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels.","date":"2007","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17203304","citation_count":100,"is_preprint":false},{"pmid":"2477081","id":"PMC_2477081","title":"Biosynthesis and assembly of platelet GPIIb-IIIa in human megakaryocytes: evidence that assembly between pro-GPIIb and GPIIIa is a prerequisite for expression of the complex on the cell surface.","date":"1989","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2477081","citation_count":94,"is_preprint":false},{"pmid":"21614411","id":"PMC_21614411","title":"Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.","date":"2011","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/21614411","citation_count":87,"is_preprint":false},{"pmid":"10531147","id":"PMC_10531147","title":"The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans.","date":"1999","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/10531147","citation_count":84,"is_preprint":false},{"pmid":"27576787","id":"PMC_27576787","title":"MiR-30a-5p Suppresses Tumor Metastasis of Human Colorectal Cancer by Targeting ITGB3.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27576787","citation_count":83,"is_preprint":false},{"pmid":"1650365","id":"PMC_1650365","title":"Phosphorylation of human platelet glycoprotein IIIa (GPIIIa). Dissociation from fibrinogen receptor activation and phosphorylation of GPIIIa in vitro.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1650365","citation_count":82,"is_preprint":false},{"pmid":"31934272","id":"PMC_31934272","title":"ITGB3/CD61: a hub modulator and target in the tumor microenvironment.","date":"2019","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/31934272","citation_count":72,"is_preprint":false},{"pmid":"25728920","id":"PMC_25728920","title":"Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort.","date":"2015","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/25728920","citation_count":70,"is_preprint":false},{"pmid":"1967954","id":"PMC_1967954","title":"Identification of an abnormal gene for the GPIIIa subunit of the platelet fibrinogen receptor resulting in Glanzmann's thrombasthenia.","date":"1990","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1967954","citation_count":69,"is_preprint":false},{"pmid":"33456563","id":"PMC_33456563","title":"CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33456563","citation_count":58,"is_preprint":false},{"pmid":"26445551","id":"PMC_26445551","title":"miR-98 targets ITGB3 to inhibit proliferation, migration, and invasion of non-small-cell lung cancer.","date":"2015","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26445551","citation_count":58,"is_preprint":false},{"pmid":"36263165","id":"PMC_36263165","title":"Platelet-derived extracellular vesicles inhibit ferroptosis and promote distant metastasis of nasopharyngeal carcinoma by upregulating ITGB3.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36263165","citation_count":56,"is_preprint":false},{"pmid":"29449539","id":"PMC_29449539","title":"G9A promotes gastric cancer metastasis by upregulating ITGB3 in a SET domain-independent manner.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29449539","citation_count":56,"is_preprint":false},{"pmid":"17559347","id":"PMC_17559347","title":"Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.","date":"2007","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/17559347","citation_count":56,"is_preprint":false},{"pmid":"8132570","id":"PMC_8132570","title":"A point mutation leads to an unpaired cysteine residue and a molecular weight polymorphism of a functional platelet beta 3 integrin subunit. The Sra alloantigen system of GPIIIa.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8132570","citation_count":52,"is_preprint":false},{"pmid":"31085188","id":"PMC_31085188","title":"LncRNA-H19 regulates cell proliferation and invasion of ectopic endometrium by targeting ITGB3 via modulating miR-124-3p.","date":"2019","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31085188","citation_count":51,"is_preprint":false},{"pmid":"1546968","id":"PMC_1546968","title":"Proteolytic dissection of the isolated platelet fibrinogen receptor, integrin GPIIb/IIIa. Localization of GPIIb and GPIIIa sequences putatively involved in the subunit interface and in intrasubunit and intrachain contacts.","date":"1992","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1546968","citation_count":51,"is_preprint":false},{"pmid":"24443232","id":"PMC_24443232","title":"MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24443232","citation_count":48,"is_preprint":false},{"pmid":"30507047","id":"PMC_30507047","title":"Role of miR-223-3p in pulmonary arterial hypertension via targeting ITGB3 in the ECM pathway.","date":"2018","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/30507047","citation_count":47,"is_preprint":false},{"pmid":"29383126","id":"PMC_29383126","title":"Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signaling and malignant features in vitro and in vivo.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29383126","citation_count":45,"is_preprint":false},{"pmid":"19691478","id":"PMC_19691478","title":"Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia.","date":"2009","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/19691478","citation_count":43,"is_preprint":false},{"pmid":"23300812","id":"PMC_23300812","title":"Multiploid CD61+ cells are the pre-dominant cell lineage infected during acute dengue virus infection in bone marrow.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23300812","citation_count":42,"is_preprint":false},{"pmid":"24675390","id":"PMC_24675390","title":"Arsenic-induced sub-lethal stress reprograms human bronchial epithelial cells to CD61¯ cancer stem cells.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24675390","citation_count":41,"is_preprint":false},{"pmid":"2345548","id":"PMC_2345548","title":"GPIIb and GPIIIa amino acid sequences deduced from human megakaryocyte cDNAs.","date":"1990","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/2345548","citation_count":40,"is_preprint":false},{"pmid":"30563517","id":"PMC_30563517","title":"Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer.","date":"2018","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30563517","citation_count":39,"is_preprint":false},{"pmid":"15344881","id":"PMC_15344881","title":"Signaling pathways of the F11 receptor (F11R; a.k.a. JAM-1, JAM-A) in human platelets: F11R dimerization, phosphorylation and complex formation with the integrin GPIIIa.","date":"2004","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/15344881","citation_count":39,"is_preprint":false},{"pmid":"19588468","id":"PMC_19588468","title":"Association and gene-gene interaction of SLC6A4 and ITGB3 in autism.","date":"2010","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19588468","citation_count":38,"is_preprint":false},{"pmid":"31836324","id":"PMC_31836324","title":"MiR-124-3p inhibits the migration and invasion of Gastric cancer by targeting ITGB3.","date":"2019","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/31836324","citation_count":37,"is_preprint":false},{"pmid":"15178823","id":"PMC_15178823","title":"A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males.","date":"2004","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/15178823","citation_count":37,"is_preprint":false},{"pmid":"9007665","id":"PMC_9007665","title":"Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression.","date":"1997","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9007665","citation_count":36,"is_preprint":false},{"pmid":"21102624","id":"PMC_21102624","title":"Family-based association study of ITGB3 in autism spectrum disorder and its endophenotypes.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/21102624","citation_count":36,"is_preprint":false},{"pmid":"29151962","id":"PMC_29151962","title":"Insufficient Radiofrequency Ablation Treated Hepatocellular Carcinoma Cells Promote Metastasis by Up-Regulation ITGB3.","date":"2017","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29151962","citation_count":36,"is_preprint":false},{"pmid":"11257275","id":"PMC_11257275","title":"The GPIIIa (beta3 integrin) PlA polymorphism in the early development of coronary atherosclerosis.","date":"2001","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11257275","citation_count":36,"is_preprint":false},{"pmid":"15817799","id":"PMC_15817799","title":"Variation in ITGB3 is associated with asthma and sensitization to mold allergen in four populations.","date":"2005","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15817799","citation_count":36,"is_preprint":false},{"pmid":"16721604","id":"PMC_16721604","title":"ITGB3 shows genetic and expression interaction with SLC6A4.","date":"2006","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16721604","citation_count":35,"is_preprint":false},{"pmid":"28600799","id":"PMC_28600799","title":"Extracellular matrix protein laminin enhances mesenchymal stem cell (MSC) paracrine function through αvβ3/CD61 integrin to reduce cardiomyocyte apoptosis.","date":"2017","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28600799","citation_count":34,"is_preprint":false},{"pmid":"33496739","id":"PMC_33496739","title":"Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/33496739","citation_count":32,"is_preprint":false},{"pmid":"17659354","id":"PMC_17659354","title":"Chicken thrombocytes express the CD51/CD61 integrin.","date":"2007","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/17659354","citation_count":32,"is_preprint":false},{"pmid":"20020534","id":"PMC_20020534","title":"AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20020534","citation_count":31,"is_preprint":false},{"pmid":"32152220","id":"PMC_32152220","title":"Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32152220","citation_count":28,"is_preprint":false},{"pmid":"27052787","id":"PMC_27052787","title":"CD142+/CD61+, CD146+ and CD45+ microparticles predict cardiovascular events in high risk patients following a Mediterranean diet supplemented with nuts.","date":"2016","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/27052787","citation_count":27,"is_preprint":false},{"pmid":"10233432","id":"PMC_10233432","title":"Homozygous Cys542-->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia.","date":"1999","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/10233432","citation_count":27,"is_preprint":false},{"pmid":"36180828","id":"PMC_36180828","title":"miR-351 promotes atherosclerosis in diabetes by inhibiting the ITGB3/PIK3R1/Akt pathway and induces endothelial cell injury and lipid accumulation.","date":"2022","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/36180828","citation_count":26,"is_preprint":false},{"pmid":"22987294","id":"PMC_22987294","title":"Role of CD61+ cells in thrombocytopenia of dengue patients.","date":"2012","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/22987294","citation_count":26,"is_preprint":false},{"pmid":"10629587","id":"PMC_10629587","title":"Interleukin-6 and interleukin-11 act synergistically with thrombopoietin and stem cell factor to modulate ex vivo expansion of human CD41+ and CD61+ megakaryocytic cells.","date":"2000","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/10629587","citation_count":26,"is_preprint":false},{"pmid":"11260058","id":"PMC_11260058","title":"Automated CD61 immunoplatelet analysis of thrombocytopenic samples.","date":"2001","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/11260058","citation_count":26,"is_preprint":false},{"pmid":"32191808","id":"PMC_32191808","title":"The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32191808","citation_count":23,"is_preprint":false},{"pmid":"35534983","id":"PMC_35534983","title":"Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/35534983","citation_count":23,"is_preprint":false},{"pmid":"33232974","id":"PMC_33232974","title":"Loss of ITGB3 in ovine conceptuses decreases conceptus expression of NOS3 and SPP1: implications for the developing placental vasculature†.","date":"2021","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/33232974","citation_count":22,"is_preprint":false},{"pmid":"31127093","id":"PMC_31127093","title":"MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31127093","citation_count":22,"is_preprint":false},{"pmid":"17983596","id":"PMC_17983596","title":"CD61 enriches long-term repopulating hematopoietic stem cells.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17983596","citation_count":22,"is_preprint":false},{"pmid":"27746115","id":"PMC_27746115","title":"Generation and Analysis of GATA2w/eGFP Human ESCs Reveal ITGB3/CD61 as a Reliable Marker for Defining Hemogenic Endothelial Cells during Hematopoiesis.","date":"2016","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27746115","citation_count":22,"is_preprint":false},{"pmid":"15834589","id":"PMC_15834589","title":"Variation in ITGB3 has sex-specific associations with plasma lipoprotein(a) and whole blood serotonin levels in a population-based sample.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15834589","citation_count":22,"is_preprint":false},{"pmid":"23628433","id":"PMC_23628433","title":"Genetic association and gene-gene interaction analyses suggest likely involvement of ITGB3 and TPH2 with autism spectrum disorder (ASD) in the Indian population.","date":"2013","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/23628433","citation_count":21,"is_preprint":false},{"pmid":"29163031","id":"PMC_29163031","title":"MicroRNA-Mediated Regulation of ITGB3 and CHL1 Is Implicated in SSRI Action.","date":"2017","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29163031","citation_count":20,"is_preprint":false},{"pmid":"36772869","id":"PMC_36772869","title":"ITGB3 promotes cisplatin resistance in osteosarcoma tumors.","date":"2023","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36772869","citation_count":19,"is_preprint":false},{"pmid":"11962738","id":"PMC_11962738","title":"Immunohistochemical analysis of beta3 integrin (CD61): expression in pig tissues and human tumors.","date":"2002","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/11962738","citation_count":19,"is_preprint":false},{"pmid":"23451109","id":"PMC_23451109","title":"Genetic variation of ITGB3 is associated with asthma in Chinese Han children.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23451109","citation_count":19,"is_preprint":false},{"pmid":"34715856","id":"PMC_34715856","title":"The long non-coding RNA HOXA11-AS activates ITGB3 expression to promote the migration and invasion of gastric cancer by sponging miR-124-3p.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34715856","citation_count":18,"is_preprint":false},{"pmid":"28091702","id":"PMC_28091702","title":"Platelet receptor Gene (P2Y12, P2Y1) and platelet glycoprotein Gene (GPIIIa) polymorphisms are associated with antiplatelet drug responsiveness and clinical outcomes after acute minor ischemic stroke.","date":"2017","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28091702","citation_count":18,"is_preprint":false},{"pmid":"33493267","id":"PMC_33493267","title":"IL1RN promotes osteoblastic differentiation via interacting with ITGB3 in osteoporosis.","date":"2021","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/33493267","citation_count":18,"is_preprint":false},{"pmid":"28068952","id":"PMC_28068952","title":"Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients.","date":"2017","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28068952","citation_count":18,"is_preprint":false},{"pmid":"34996170","id":"PMC_34996170","title":"Compliant Substratum Changes Osteocyte Functions: The Role of ITGB3/FAK/β-Catenin Signaling Matters.","date":"2018","source":"ACS applied bio materials","url":"https://pubmed.ncbi.nlm.nih.gov/34996170","citation_count":18,"is_preprint":false},{"pmid":"28256590","id":"PMC_28256590","title":"CD61 promotes the differentiation of canine ADMSCs into PGC-like cells through modulation of TGF-β signaling.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28256590","citation_count":18,"is_preprint":false},{"pmid":"32370146","id":"PMC_32370146","title":"Diabetes and Hyperglycemia Affect Platelet GPIIIa Expression. Effects on Adhesion Potential of Blood Platelets from Diabetic Patients under In Vitro Flow Conditions.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32370146","citation_count":16,"is_preprint":false},{"pmid":"27233747","id":"PMC_27233747","title":"Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.","date":"2016","source":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/27233747","citation_count":16,"is_preprint":false},{"pmid":"36035754","id":"PMC_36035754","title":"CRISPR-mediated activation of autism gene Itgb3 restores cortical network excitability via mGluR5 signaling.","date":"2022","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/36035754","citation_count":15,"is_preprint":false},{"pmid":"26840189","id":"PMC_26840189","title":"Overexpression of CD61 promotes hUC-MSC differentiation into male germ-like cells.","date":"2016","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/26840189","citation_count":15,"is_preprint":false},{"pmid":"28837027","id":"PMC_28837027","title":"Expression of PGR, HBEGF, ITGAV, ITGB3 and SPP1 genes in eutopic endometrium of infertile women with endometriosis during the implantation window: a pilot study.","date":"2017","source":"JBRA assisted reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/28837027","citation_count":15,"is_preprint":false},{"pmid":"15914300","id":"PMC_15914300","title":"Thrombotic thrombocytopenic purpura causing rapid unexpected death: value of CD61 immunohistochemical staining in diagnosis.","date":"2005","source":"Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15914300","citation_count":15,"is_preprint":false},{"pmid":"24474638","id":"PMC_24474638","title":"Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.","date":"2014","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24474638","citation_count":15,"is_preprint":false},{"pmid":"11606818","id":"PMC_11606818","title":"Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process.","date":"2001","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/11606818","citation_count":15,"is_preprint":false},{"pmid":"38561495","id":"PMC_38561495","title":"Unconventional human CD61 pairing with CD103 promotes TCR signaling and antigen-specific T cell cytotoxicity.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38561495","citation_count":14,"is_preprint":false},{"pmid":"28905013","id":"PMC_28905013","title":"Common rs5918 (PlA1/A2) polymorphism in the ITGB3 gene and risk of coronary artery disease.","date":"2016","source":"Archives of medical sciences. Atherosclerotic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28905013","citation_count":14,"is_preprint":false},{"pmid":"35777302","id":"PMC_35777302","title":"microRNA-25-3p suppresses osteogenic differentiation of BMSCs in patients with osteoporosis by targeting ITGB3.","date":"2022","source":"Acta histochemica","url":"https://pubmed.ncbi.nlm.nih.gov/35777302","citation_count":14,"is_preprint":false},{"pmid":"27488401","id":"PMC_27488401","title":"Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness.","date":"2016","source":"International heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/27488401","citation_count":14,"is_preprint":false},{"pmid":"2900503","id":"PMC_2900503","title":"A Taq 1 polymorphism for the human platelet glycoprotein IIIa gene (GP3A).","date":"1988","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2900503","citation_count":14,"is_preprint":false},{"pmid":"30535103","id":"PMC_30535103","title":"Evidence that ITGB3 promoter variants increase serotonin blood levels by regulating platelet serotonin transporter trafficking.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30535103","citation_count":13,"is_preprint":false},{"pmid":"33047245","id":"PMC_33047245","title":"Significant reductions in apoptosis-related proteins (HSPA6, HSPA8, ITGB3, YWHAH, and PRDX6) are involved in immune thrombocytopenia.","date":"2020","source":"Journal of thrombosis and thrombolysis","url":"https://pubmed.ncbi.nlm.nih.gov/33047245","citation_count":13,"is_preprint":false},{"pmid":"9459345","id":"PMC_9459345","title":"Functional characterization of PM6/13, a beta3-specific (GPIIIa/CD61) monoclonal antibody that shows preferential inhibition of fibrinogen binding over fibronectin binding to activated human platelets.","date":"1998","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/9459345","citation_count":13,"is_preprint":false},{"pmid":"1549507","id":"PMC_1549507","title":"Microsatellite polymorphism in the human platelet glycoprotein IIIa gene (GP3A) on chromosome 17.","date":"1992","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1549507","citation_count":13,"is_preprint":false},{"pmid":"38951640","id":"PMC_38951640","title":"PEX3 promotes regenerative repair after myocardial injury in mice through facilitating plasma membrane localization of ITGB3.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/38951640","citation_count":12,"is_preprint":false},{"pmid":"23860687","id":"PMC_23860687","title":"Genetic association analysis of ITGB3 polymorphisms with age at onset of schizophrenia.","date":"2013","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/23860687","citation_count":12,"is_preprint":false},{"pmid":"37760946","id":"PMC_37760946","title":"ITCH-Mediated Ubiquitylation of ITGB3 Promotes Cell Proliferation and Invasion of Ectopic Endometrial Stromal Cells in Ovarian Endometriosis.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/37760946","citation_count":12,"is_preprint":false},{"pmid":"18234279","id":"PMC_18234279","title":"Platelet CD61 expression in vascular calcineurin inhibitor toxicity of renal allografts.","date":"2008","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18234279","citation_count":12,"is_preprint":false},{"pmid":"36130933","id":"PMC_36130933","title":"MIIP functions as a novel ligand for ITGB3 to inhibit angiogenesis and tumorigenesis of triple-negative breast cancer.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36130933","citation_count":12,"is_preprint":false},{"pmid":"24777809","id":"PMC_24777809","title":"SNPs in microRNA-binding sites in the ITGB1 and ITGB3 3'-UTR increase colorectal cancer risk.","date":"2014","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/24777809","citation_count":12,"is_preprint":false},{"pmid":"12714203","id":"PMC_12714203","title":"Association between the Pl(A) platelet glycoprotein GPIIIa polymorphism and extent of coronary artery disease.","date":"2003","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/12714203","citation_count":12,"is_preprint":false},{"pmid":"8095357","id":"PMC_8095357","title":"Application of GPIIIa gene Taq I polymorphism to determination of carrier status in Glanzmann's thrombasthenia families of Chinese origin.","date":"1993","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/8095357","citation_count":12,"is_preprint":false},{"pmid":"21113249","id":"PMC_21113249","title":"Novel Mutations in the GPIIb and GPIIIa Genes in Glanzmann Thrombasthenia.","date":"2010","source":"Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie","url":"https://pubmed.ncbi.nlm.nih.gov/21113249","citation_count":12,"is_preprint":false},{"pmid":"37062956","id":"PMC_37062956","title":"Reduced expression of Il10, Stat3, Hoxa10, and Itgb3 in the embryo implantation site of rat model with prenatal androgen-induced polycystic ovary syndrome.","date":"2023","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/37062956","citation_count":11,"is_preprint":false},{"pmid":"19345676","id":"PMC_19345676","title":"A1/A2 polymorphism of GpIIIa gene and a risk of aneurysmal subarachnoid haemorrhage.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19345676","citation_count":11,"is_preprint":false},{"pmid":"31218593","id":"PMC_31218593","title":"An Evaluation of CD61 Immunohistochemistry in Identification of Vascular Invasion in Follicular Thyroid Neoplasms.","date":"2019","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31218593","citation_count":11,"is_preprint":false},{"pmid":"29050321","id":"PMC_29050321","title":"Interaction among CYP2C8, GPIIIa and P2Y12 variants increase susceptibility to ischemic stroke in Chinese population.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29050321","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55297,"output_tokens":7408,"usd":0.138506,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16672,"output_tokens":5548,"usd":0.11103,"stage2_stop_reason":"end_turn"},"total_usd":0.249536,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"Assembly between pro-GPIIb and GPIIIa (ITGB3) is an obligatory prerequisite for maturation of the heterodimer and its expression on the cell surface; unassociated GPIIIa is retained intracellularly and not surface-exposed.\",\n      \"method\": \"Pulse-chase experiments with antibodies specific for GPIIIa or GPIIb in human megakaryocytes; LAMA-84 megakaryocytic cell line expressing only pro-GPIIb showed no surface expression of GPIIIa until GPIIb processing occurred upon GPIIIa co-expression\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in megakaryocyte culture + cell line complementation experiment, clear functional readout (surface expression), replicated across two experimental systems\",\n      \"pmids\": [\"2477081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"GPIIIa (ITGB3) is phosphorylated in platelets predominantly on threonine; Ca2+/calmodulin-dependent kinase II can phosphorylate purified GPIIIa to ~0.5 mol P/mol in vitro; stoichiometry in intact platelets is very low (~0.01–0.03 mol P/mol), suggesting phosphorylation does not affect bulk fibrinogen-receptor function but may affect a subpopulation.\",\n      \"method\": \"Metabolic 32Pi labeling of intact platelets; in vitro phosphorylation of purified GPIIb-IIIa by PKC and CaM kinase II; phosphoamino acid analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assay with purified proteins + stoichiometric quantification in intact platelets, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"1650365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Limited proteolysis of isolated GPIIb/IIIa heterodimer mapped a ligand-binding region to GPIIIa residues 100–220 and identified GPIIIa residues 217–421 as involved in the subunit interface; the GPIIIa N-terminal (1–52) and core (423–622) domains are compact, while the intervening region is proteolysis-susceptible.\",\n      \"method\": \"Limited proteolysis of purified GPIIb/IIIa with proteinases of different specificities followed by protein-chemical and immunochemical analysis of peptide fragments\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro biochemical dissection with multiple proteinases and immunochemical mapping, single lab, no crystal structure confirmation\",\n      \"pmids\": [\"1546968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A C→T point mutation at position 2004 in GPIIIa creates an Arg636→Cys substitution that introduces an unpaired cysteine in the cysteine-rich domain, alters N-linked glycosylation (detected as molecular weight shift reversed by EndoH), and creates the Sra alloantigen epitope; despite this, surface expression of GPIIb-IIIa and platelet aggregation are unaffected.\",\n      \"method\": \"PCR-amplified GPIIIa mRNA sequencing; allele-specific recombinant GPIIIa expression; anti-Sra alloantibody reactivity assay; Endoglycosidase H treatment; SDS-PAGE; platelet aggregation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — recombinant expression with site-specific variant + functional validation (aggregation) + glycosylation mapping, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"8132570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A homozygous Cys542→Arg substitution in GPIIIa disrupts disulfide bond formation in the cysteine-rich core region, resulting in a slightly slower-migrating GPIIIa by Western blot and trace levels of both GPIIb and GPIIIa at the platelet surface (type I Glanzmann's thrombasthenia), and also reduces αvβ3 surface expression.\",\n      \"method\": \"Western blotting; flow cytometry with mAbs to GPIIb, GPIIIa, GPIIb-IIIa and αv; PCR-SSCP and direct sequencing; allele-specific restriction enzyme analysis (HinP1I site introduced by mutation)\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (WB, flow cytometry, sequencing, restriction analysis) in single patient/family, clear structure-function link\",\n      \"pmids\": [\"10233432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"F11R (JAM-1) forms a complex with integrin GPIIIa (ITGB3) on platelet surfaces following F11R crosslinking, coincident with F11R dimerization and phosphorylation; this association is part of the signaling cascade leading to platelet aggregation and secretion.\",\n      \"method\": \"Co-immunoprecipitation of F11R with GPIIIa from activated platelets; functional assays (aggregation, granule secretion); calcium measurements; actin assembly assays\",\n      \"journal\": \"Journal of receptor and signal transduction research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single co-IP with functional follow-up in platelet system, multiple orthogonal functional assays, single lab\",\n      \"pmids\": [\"15344881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Several missense mutations in ITGB3 (e.g., C38Y, M118R, G221D) prevent αIIbβ3 complex expression at the COS-7 cell surface; a K253M substitution of β3 defines a key role of K253 in the interaction between the αIIb β-propeller and β3 β-I domains, as revealed by free energy analysis on the resolved αIIbβ3 crystal structure.\",\n      \"method\": \"Site-directed mutagenesis; transient expression in COS-7 cells; flow cytometry; structural free energy analysis on solved αIIbβ3 structure; molecular modeling\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis + cell surface expression assay + structural modeling on solved crystal structure, multiple mutations tested, single lab\",\n      \"pmids\": [\"20020534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ROS upregulate ITGB3 expression in colorectal cancer cells, and surface expression as αvβ3 heterodimer is required for ITGB3-mediated migration and invasion; ITGB3 promotes aggressive phenotype through the PI3K-Akt-mTOR pathway and upregulation of STMN1.\",\n      \"method\": \"2D-electrophoresis proteomics; knockdown of ITGB3 by siRNA in SW620 and H2O2-treated SW480 cells; Transwell migration/invasion assays; Western blot; ROS measurement\",\n      \"journal\": \"Molecular & cellular proteomics : MCP\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function KD with defined phenotypic readout + pathway analysis, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21622897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Integrin β3 (CD61) signaling is required for sustaining active TGFβ signaling and self-renewal of breast tumor-initiating cells in the MMTV-Her2/neu model; pharmacological inhibition of TGFβ signaling suppressed TIC self-renewal and clonogenicity.\",\n      \"method\": \"CD49f/CD61 surface marker sorting; tumorsphere formation assay; in vivo tumorigenicity; TGFβ pathway inhibition; gene expression profiling\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function pharmacological inhibition with functional phenotype (self-renewal, tumorigenicity), single lab, multiple assays\",\n      \"pmids\": [\"21996747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ITGB3 is translationally activated under hypoxia in breast cancer cells (mTOR-independent mechanism), and is required for sustained TGF-β pathway activation and induction of Snail/EMT markers; ITGB3 knockdown increased apoptosis, reduced migration, and significantly reduced lung metastasis in mice.\",\n      \"method\": \"Polysomal RNA-Seq (translatome profiling); ITGB3 knockdown; apoptosis assays; TGF-β pathway reporter; EMT marker analysis; in vivo lung metastasis mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — translatome profiling + KD with multiple orthogonal functional readouts (apoptosis, migration, EMT, in vivo metastasis) and pathway mechanistic link\",\n      \"pmids\": [\"29383126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"G9A promotes ITGB3 expression in gastric cancer by forming a transcriptional activator complex with P300 and glucocorticoid receptor (GR) at the ITGB3 promoter, an effect dependent on dexamethasone but independent of G9A's SET domain methyltransferase activity.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); co-immunoprecipitation of G9A/P300/GR complex; luciferase reporter assay; ITGB3 overexpression/knockdown; in vitro and in vivo invasion/metastasis assays; SET domain mutant constructs\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP, reciprocal co-IP, reporter assay, and mutant constructs establishing transcriptional mechanism, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"29449539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ITGB3 depletion sensitizes mesenchymal lung cancer cells to conventional chemotherapeutic drugs by modulating the NF-κB signaling pathway.\",\n      \"method\": \"ITGB3 knockdown; cell viability assays; NF-κB signaling pathway analysis; large-scale transcriptome and drug-response dataset correlation\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — KD with defined pathway readout (NF-κB) and chemosensitivity phenotype, single lab, limited mechanistic depth in abstract\",\n      \"pmids\": [\"30563517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ITGB3 promoter variant rs55827077 (C allele) enhances ITGB3 promoter activity specifically during megakaryocyte differentiation, leading to greater integrin β3 protein expression, enhanced SERT trafficking from cytosol to platelet plasma membrane, and elevated serotonin blood levels.\",\n      \"method\": \"Luciferase reporter assays in K-562 and HEL 92.1.7 hematopoietic cell lines; ITGB3 sequencing; platelet integrin β3 protein quantification; SERT trafficking assay; association analysis in 176 autistic individuals\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional promoter reporter assay + protein expression measurement + SERT trafficking assay, replicated across cell lines and associated with human phenotype data\",\n      \"pmids\": [\"30535103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ITGB3 facilitates uptake of small extracellular vesicles in breast cancer cells through interaction with heparan sulfate proteoglycans (HSPGs) and integrin endocytosis; this requires activation of focal adhesion kinase (FAK), which is necessary for endocytosis-mediated internalization of vesicles.\",\n      \"method\": \"ITGB3 knockdown/overexpression; vesicle uptake assays; Co-IP of ITGB3 with HSPGs; FAK inhibition; endocytosis inhibitor experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction data + KD/KO with defined cellular phenotype + FAK pathway validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32848136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In melanoma tumor-repopulating cells, ITGB3 activates c-SRC, which phosphorylates STAT3; STAT3 transcriptionally suppresses RIG-I, thereby decreasing STAT1 activation and conferring resistance to IFN-α-induced apoptosis.\",\n      \"method\": \"ITGB3/c-SRC/STAT3 knockdown; ChIP-qPCR for STAT3 binding to RIG-I promoter; Co-IP of SHP-1 with STAT1; Western blot; apoptosis assays; in vivo tumor models\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR + co-IP + KD with defined apoptosis phenotype + in vivo validation, single lab with multiple orthogonal methods establishing signaling pathway\",\n      \"pmids\": [\"32152220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EGFL7 binds to and activates ITGB3 on multiple myeloma cells, causing ITGB3 phosphorylation and focal adhesion kinase activation; ITGB3 overexpression upregulates KLF2 transcription factor, which in turn enhances EGFL7 transcription, establishing an EGFL7-ITGB3-KLF2 amplification loop supporting MM cell survival.\",\n      \"method\": \"ITGB3 and EGFL7 overexpression/knockdown; ITGB3 phosphorylation assay; FAK activation measurement; KLF2 reporter; neutralizing antibody treatment; in vivo mouse transplantation model\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation assay + multiple KD/KO + reporter assay + in vivo model, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32191808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-30 family deficiency activates calcineurin-NFATC signaling, which in turn activates uPAR-ITGB3 signaling in podocytes, leading to Rho GTPase activation, synaptopodin downregulation and podocyte injury; ITGB3 inhibition, calcineurin inhibition, or NFATC inhibition each reduces the effects of miR-30 knockdown.\",\n      \"method\": \"Podocyte-specific miR-30 KO and transgenic mice; ITGB3 inhibitor treatment; calcineurin/NFATC inhibitors; uPAR/ITGB3 pathway measurement; proteinuria readout; LPS model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO + pharmacological rescue + multiple inhibitors establishing pathway epistasis, in vivo and in vitro corroboration\",\n      \"pmids\": [\"31127093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HOXB5 transcriptionally activates ITGB3 expression by directly binding to the ITGB3 promoter (chromatin immunoprecipitation + luciferase assay), promoting colorectal cancer metastasis; CXCL12 upregulates HOXB5 via ERK/ETS1 pathway, creating a CXCL12-HOXB5-CXCR4 positive feedback loop.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); luciferase reporter assay; HOXB5 overexpression/knockdown; in vivo lung and liver metastasis models\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP and luciferase reporter directly establishing transcriptional regulation + in vivo metastasis validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33456563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss of ITGB3 in ovine conceptus trophectoderm decreases embryo growth and reduces expression of SPP1 and NOS3 in the placental allantoic membrane, implicating ITGB3 in regulation of placental vascular development.\",\n      \"method\": \"Morpholino antisense oligonucleotide knockdown of ITGB3 in sheep uterus; measurement of embryo growth; qPCR and immunolocalization of SPP1 and NOS3\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo morpholino KD with defined molecular phenotype (NOS3, SPP1 reduction) and growth readout, single lab\",\n      \"pmids\": [\"33232974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL1RN interacts with ITGB3 (integrin β3) to activate β-catenin signaling, which regulates osteoblast differentiation; IL1RN overexpression promotes osteogenic markers and IL1RN silencing attenuates osteogenesis.\",\n      \"method\": \"Co-immunoprecipitation of IL1RN and ITGB3; IL1RN overexpression/knockdown in MC3T3-E1 and C3H10T1/2 cells; osteogenic staining and marker expression; β-catenin signaling measurement\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single co-IP with functional follow-up (gain/loss of function + pathway measurement), single lab\",\n      \"pmids\": [\"33493267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ITGB3 haplo-insufficiency in cortical neurons impairs network excitability by promoting extra-synaptic over synaptic mGluR5 signaling; CRISPR activation of Itgb3 to restore gene dosage rebalanced network excitability as effectively as MPEP (mGluR5 antagonist) blockade.\",\n      \"method\": \"Itgb3 knockout mice; CRISPR activation (CRISPRa) to restore Itgb3 expression; cortical network excitability recording; mGluR5 pharmacological manipulation; biochemical and imaging analyses\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO + CRISPRa rescue + pharmacological epistasis establishing functional interaction with mGluR5, multiple orthogonal methods in single study\",\n      \"pmids\": [\"36035754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"P-EV (platelet-derived extracellular vesicle)-upregulated ITGB3 increases SLC7A11 expression by enhancing protein stability and activating the MAPK/ERK/ATF4/Nrf2 axis, suppressing ferroptosis and facilitating NPC cell metastasis.\",\n      \"method\": \"EV transfer experiments; ITGB3 overexpression/knockdown; SLC7A11 protein stability assay; MAPK/ERK/ATF4/Nrf2 pathway analysis; ferroptosis assays; NPC xenograft mouse model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function + pathway analysis + in vivo validation, single lab\",\n      \"pmids\": [\"36263165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MIIP directly interacts with ITGB3 via an RGD motif, suppresses ITGB3 downstream signaling, reduces β-catenin (via ubiquitin-mediated degradation), decreases VEGFA production and EMT, thereby inhibiting tumor angiogenesis and metastasis of triple-negative breast cancer.\",\n      \"method\": \"Co-immunoprecipitation of MIIP and ITGB3; RGD motif mutagenesis; β-catenin ubiquitination assay; VEGFA expression; in vivo tumor models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct binding shown by co-IP + RGD motif mutagenesis validating binding site + downstream pathway and in vivo functional readout, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36130933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ITCH (ubiquitin E3 ligase) interacts with ITGB3 and mediates its ubiquitylation; ITCH overexpression opposes ITGB3-promoted proliferation and invasion of ectopic endometrial stromal cells, suggesting ubiquitination of ITGB3 regulates its stability/activity.\",\n      \"method\": \"Co-immunoprecipitation of ITCH and ITGB3; ubiquitylation analysis; CCK8 proliferation assay; Transwell invasion assay; ITGB3 and ITCH overexpression\",\n      \"journal\": \"Biomedicines\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with ubiquitylation assay + functional rescue experiments, single lab\",\n      \"pmids\": [\"37760946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ITGB3 (CD61) is transiently expressed on T cells, pairs with CD103 at synaptic microclusters, and colocalizes with the TCR; CD61 modulates downstream TCR signaling and enhances antitumor cytotoxicity.\",\n      \"method\": \"Live imaging of synaptic microclusters; co-localization of CD61 with CD103 and TCR; TCR signaling pathway analysis; cytotoxicity assays; in vivo tumor growth control experiments\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — imaging of CD61/CD103/TCR colocalization at immune synapse + functional cytotoxicity assays + in vivo tumor control, single study with multiple orthogonal methods\",\n      \"pmids\": [\"38561495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PEX3-regulated plasmalogen metabolism activates the AKT/GSK3β signaling pathway via plasma membrane localization of ITGB3, promoting myocardial regenerative repair; cardiomyocyte-specific Pex3 KO disrupts ITGB3 plasma membrane localization.\",\n      \"method\": \"Cardiomyocyte-specific Pex3 KO mice; lipid metabolomics; ITGB3 plasma membrane fractionation; AKT/GSK3β signaling measurement; myocardial regeneration readouts\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO + metabolomics + subcellular fractionation establishing ITGB3 membrane localization mechanism + signaling pathway, single lab\",\n      \"pmids\": [\"38951640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Laminin (ECM protein) enhances MSC paracrine function (GRO-α, HGF, IL-8 secretion) through αvβ3 integrin (ITGB3), with GRO-α and IL-8 secretion dependent on JNK signaling and HGF secretion dependent on PI3K/AKT signaling downstream of αvβ3.\",\n      \"method\": \"αvβ3 integrin blocking antibody; JNK and PI3K/AKT inhibitors; paracrine factor ELISA; cardiomyocyte apoptosis assay\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor blocking + pathway inhibitors with defined secretion phenotype, single lab, multiple signaling arms validated\",\n      \"pmids\": [\"28600799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Osteocytes sense ECM mechanical stiffness via integrin αvβ3 (containing ITGB3), which interacts with FAK to transduce extracellular mechanical stimuli into intracellular signals; FAK triggers cytoplasmic β-catenin signaling and nuclear translocation, affecting gap junction function and mineralization activity.\",\n      \"method\": \"PDMS substrates with varied mechanical stiffness; ITGB3/FAK inhibitor experiments; β-catenin nuclear localization assay; gap junction and mineralization activity measurement\",\n      \"journal\": \"ACS applied bio materials\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanically defined substrate + inhibitor experiments establishing ITGB3-FAK-β-catenin pathway in mechanosensing, single lab\",\n      \"pmids\": [\"34996170\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ITGB3 (integrin β3/GPIIIa/CD61) encodes the β3 subunit of the αIIbβ3 fibrinogen receptor and αvβ3 vitronectin receptor; it requires assembly with pro-αIIb in the ER as a prerequisite for surface expression, is phosphorylated at low stoichiometry by CaM kinase II on threonine residues, mediates outside-in signaling through FAK activation to drive migration, invasion, vesicle endocytosis, and TGF-β/mGluR5 pathway regulation; its expression is transcriptionally regulated by HOXB5 and G9A/P300/GR complexes, translationally activated by hypoxia, post-translationally controlled by ITCH-mediated ubiquitylation, and at the platelet surface it forms signaling complexes with F11R/JAM-A; through a protein complex involving integrin β3, platelet SERT trafficking to the membrane is regulated, linking ITGB3 to serotonin blood levels; and in T cells, transient CD61 expression at the immune synapse with CD103 potentiates TCR signaling and antitumor cytotoxicity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ITGB3 (integrin β3/GPIIIa/CD61) is the β-subunit of integrin heterodimers that transduce extracellular adhesion cues into intracellular signaling controlling platelet aggregation, cell migration, invasion, and tissue remodeling [#0, #7]. Surface display of the receptor is conditional: GPIIIa must assemble with pro-GPIIb in the ER as an obligatory prerequisite for heterodimer maturation, and unassembled GPIIIa is retained intracellularly [#0]; mutations disrupting subunit-interface contacts or disulfide bonding in the cysteine-rich region abolish surface expression of both αIIbβ3 and αvβ3, causing Glanzmann's thrombasthenia [#4, #6]. Engagement of αvβ3 drives outside-in signaling principally through focal adhesion kinase (FAK), which couples the receptor to integrin endocytosis and extracellular-vesicle uptake, to β-catenin nuclear translocation during mechanosensing, and to PI3K/AKT- and JNK-dependent outputs [#13, #27, #26]. Across multiple cancers, ITGB3 sustains TGF-β signaling, EMT, and metastasis, and engages additional effector axes including PI3K-Akt-mTOR/STMN1, c-SRC/STAT3, NF-κB, and EGFL7-KLF2 amplification loops [#7, #9, #14, #15]. ITGB3 abundance is set at several levels: transcriptionally by HOXB5 and by a G9A/P300/glucocorticoid-receptor activator complex, translationally by hypoxia, and post-translationally by ITCH-mediated ubiquitylation; a promoter variant raising β3 expression in megakaryocytes enhances SERT trafficking to the platelet membrane and elevates blood serotonin [#17, #10, #9, #23, #12]. Beyond hemostasis and cancer, ITGB3 acts as a uPAR-linked effector of calcineurin-NFATC signaling in podocyte injury, regulates cortical network excitability by balancing synaptic versus extrasynaptic mGluR5 signaling, and is transiently expressed on T cells where it pairs with CD103 at the immune synapse to potentiate TCR signaling and antitumor cytotoxicity [#16, #20, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established that GPIIIa cannot reach the cell surface alone, defining heterodimer assembly with pro-GPIIb as the gatekeeping step for receptor biogenesis.\",\n      \"evidence\": \"Pulse-chase with subunit-specific antibodies in human megakaryocytes and complementation in the LAMA-84 cell line\",\n      \"pmids\": [\"2477081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the ER chaperones or quality-control machinery enforcing retention\", \"Does not address αvβ3 assembly requirements\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Determined that GPIIIa is phosphorylated on threonine by CaM kinase II, but at stoichiometry too low to regulate bulk fibrinogen-receptor function.\",\n      \"evidence\": \"32Pi metabolic labeling of platelets plus in vitro phosphorylation of purified GPIIb-IIIa and phosphoamino acid analysis\",\n      \"pmids\": [\"1650365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological role of the low-stoichiometry phosphorylation not resolved\", \"Specific phosphoacceptor residues not mapped\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Mapped the ligand-binding and subunit-interface regions of GPIIIa by proteolytic dissection, providing the first domain-level structure-function framework.\",\n      \"evidence\": \"Limited proteolysis of purified GPIIb/IIIa with multiple proteinases and immunochemical fragment mapping\",\n      \"pmids\": [\"1546968\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure confirmation at the time\", \"Boundaries inferred from protease accessibility rather than direct contact mapping\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected disease mutations to receptor assembly defects and identified specific β3 residues governing the αIIb β-propeller/β3 β-I domain interface.\",\n      \"evidence\": \"Site-directed mutagenesis and COS-7 surface expression assays combined with free-energy analysis on the solved αIIbβ3 crystal structure\",\n      \"pmids\": [\"20020534\", \"10233432\", \"8132570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address how interface defects are sensed by ER quality control\", \"Some variants (e.g. Sra) alter glycosylation without affecting function, leaving structural consequences unexplained\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified a platelet-surface signaling partnership in which F11R/JAM-A associates with GPIIIa during platelet activation.\",\n      \"evidence\": \"Co-immunoprecipitation from activated platelets with functional aggregation, secretion, calcium and actin assays\",\n      \"pmids\": [\"15344881\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single co-IP without reciprocal validation\", \"Direct versus indirect nature of the association not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined αvβ3 as the receptor coupling laminin engagement to MSC paracrine secretion through branched JNK and PI3K/AKT outputs.\",\n      \"evidence\": \"αvβ3 blocking antibody plus JNK and PI3K/AKT inhibitors with paracrine factor ELISA\",\n      \"pmids\": [\"28600799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antibody blockade does not exclude contribution of other αv heterodimers\", \"Mechanism connecting receptor to divergent kinase arms not detailed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed that ITGB3 drives tumor migration/invasion and TGF-β-dependent tumor-initiating-cell self-renewal, placing the receptor upstream of cancer-progression programs.\",\n      \"evidence\": \"siRNA knockdown with Transwell assays and PI3K-Akt-mTOR/STMN1 analysis; CD49f/CD61 sorting with tumorsphere and in vivo tumorigenicity assays plus TGF-β inhibition\",\n      \"pmids\": [\"21622897\", \"21996747\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ROS upregulates ITGB3 transcription not defined\", \"Direct molecular link between β3 and TGF-β receptor activation not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established that ITGB3 abundance is set translationally under hypoxia and is required for sustained TGF-β/EMT signaling and metastasis.\",\n      \"evidence\": \"Polysomal RNA-Seq translatome profiling plus knockdown with apoptosis, migration, EMT readouts and in vivo lung metastasis\",\n      \"pmids\": [\"29383126\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mTOR-independent translational mechanism not molecularly identified\", \"Effector linking β3 to Snail induction unspecified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified multiple transcriptional and signaling inputs setting or transmitting ITGB3 levels in cancer, including a non-catalytic G9A/P300/GR activator complex and NF-κB-linked chemoresistance.\",\n      \"evidence\": \"ChIP, reciprocal co-IP, luciferase reporters and SET-domain mutants for G9A complex; knockdown with NF-κB pathway and drug-response analysis for mesenchymal lung cancer\",\n      \"pmids\": [\"29449539\", \"30563517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of glucocorticoid-dependent ITGB3 induction beyond gastric cancer untested\", \"Mechanism linking β3 to NF-κB activation not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked an ITGB3 promoter variant to megakaryocyte-specific β3 expression, SERT membrane trafficking, and blood serotonin, connecting integrin dosage to a neurotransmitter phenotype.\",\n      \"evidence\": \"Luciferase reporters in hematopoietic cell lines, platelet β3 quantification, SERT trafficking assay, and human association analysis\",\n      \"pmids\": [\"30535103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which β3 promotes SERT membrane trafficking unresolved\", \"Causality between serotonin elevation and phenotype not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed ITGB3 as a downstream effector in the miR-30/calcineurin-NFATC/uPAR axis driving podocyte injury.\",\n      \"evidence\": \"Podocyte-specific miR-30 KO/transgenic mice with ITGB3, calcineurin and NFATC inhibitors and proteinuria readouts\",\n      \"pmids\": [\"31127093\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct uPAR-ITGB3 binding versus signaling crosstalk not dissected\", \"Rho GTPase activation mechanism downstream of β3 not detailed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined FAK-dependent outside-in signaling roles for ITGB3 in vesicle endocytosis and in SRC/STAT3 and EGFL7-KLF2 survival circuits.\",\n      \"evidence\": \"Knockdown/overexpression with reciprocal co-IP (HSPGs, EGFL7), FAK inhibition, ChIP-qPCR, phosphorylation and in vivo models across breast cancer, melanoma and myeloma\",\n      \"pmids\": [\"32848136\", \"32152220\", \"32191808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether a single β3 conformation drives all these effector branches unknown\", \"Cell-type determinants selecting among SRC/STAT3, KLF2 and FAK outputs unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified HOXB5 as a direct transcriptional activator of ITGB3 in a CXCL12-CXCR4 feedback loop and extended ITGB3 function to placental vascular development and osteoblast differentiation.\",\n      \"evidence\": \"ChIP and luciferase reporters with in vivo metastasis for HOXB5; morpholino knockdown in sheep conceptus; IL1RN-ITGB3 co-IP with β-catenin/osteogenesis assays\",\n      \"pmids\": [\"33456563\", \"33232974\", \"33493267\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"IL1RN-ITGB3 interaction rests on a single co-IP\", \"Mechanism by which β3 controls SPP1/NOS3 in placenta not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded ITGB3 regulation and signaling to RGD-mediated suppression by MIIP, ferroptosis evasion via SLC7A11, and neuronal control of mGluR5-dependent network excitability.\",\n      \"evidence\": \"Co-IP with RGD-motif mutagenesis and β-catenin ubiquitination (MIIP); EV transfer with SLC7A11 stability and MAPK/ERK/ATF4/Nrf2 analysis; Itgb3 KO mice with CRISPRa rescue and mGluR5 pharmacology\",\n      \"pmids\": [\"36130933\", \"36263165\", \"36035754\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether synaptic mGluR5 regulation involves canonical integrin adhesion signaling unknown\", \"Structural basis of MIIP RGD-mediated inhibition versus ligand activation not contrasted\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established ITCH-mediated ubiquitylation as a post-translational control of ITGB3 stability and pro-invasive activity.\",\n      \"evidence\": \"Co-IP of ITCH with ITGB3, ubiquitylation analysis, and proliferation/invasion rescue in ectopic endometrial stromal cells\",\n      \"pmids\": [\"37760946\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitylated lysine residues and chain type not mapped\", \"Whether ITCH targets cell-surface or intracellular β3 pools unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed non-canonical contexts: transient CD61 expression at the T-cell immune synapse potentiating TCR signaling, and PEX3-dependent plasmalogen metabolism controlling ITGB3 membrane localization in cardiac repair.\",\n      \"evidence\": \"Live synaptic imaging with CD61/CD103/TCR colocalization and cytotoxicity assays; cardiomyocyte-specific Pex3 KO with lipidomics, membrane fractionation and AKT/GSK3β analysis\",\n      \"pmids\": [\"38561495\", \"38951640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CD61 mechanistically modulates TCR proximal signaling not defined\", \"Lipid-dependent mechanism positioning β3 at the plasma membrane not molecularly resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single β3 subunit selects among its diverse outside-in effector branches (FAK, SRC/STAT3, β-catenin, NF-κB, mGluR5) in a cell-type- and ligand-specific manner.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying conformational or partner-selection model across tissues\", \"Relationship between phosphorylation, ubiquitylation and effector choice unmapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 13, 26, 27]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [13, 27, 14, 15, 16]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [5, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 12, 25]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 14, 15, 16, 27]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 5, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 9, 14, 15, 22]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 17]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [23, 1]}\n    ],\n    \"complexes\": [\"αIIbβ3 (GPIIb-IIIa)\", \"αvβ3 integrin\"],\n    \"partners\": [\"ITGAV\", \"ITGA2B\", \"F11R\", \"EGFL7\", \"MIIP\", \"IL1RN\", \"ITCH\", \"CD103\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}